Prostate Specific Antigen Dynamics and Features in Prostate Cancer
By:
References
- Arlen, P. M., Bianco, F., Dahut, W. L. (2008). Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J. Urol., 179 (6), 2181–2185; discussion 2185–2186.10.1016/j.juro.2008.01.099
- Bartsch, G., Horninger, W., Klocker, H. (2001). Prostate cancer mortality after introduction of prostate specific antigen mass screening in the Federal State of Tyrol, Austria. Urology, 58 (3), 417–424.10.1016/S0090-4295(01)01264-X
- Billis, A., Guimaraes, M. S., Freitas, L. L. (2008). The impact of the 2005 International Society of Urological Pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biop-sies. J. Urol., 180 (2), 548–5452; discussion 552–553.10.1016/j.juro.2008.04.018
- Carter, H. B., Pearson, J. D., Metter, E. J. (1992). Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA, 267 (16), 2215–2220.10.1001/jama.1992.03480160073037
- Choo, R., Klotz, L., Deboer, G., Danjoux, C., Morton, G. (2004). Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma. Brit. J. Urol. Int., 94 (3), 295–298.10.1111/j.1464-410X.2004.04926.x
- D’Amico, A. V., Hanks, G. E. (1993). Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer, 72 (9), 2638–2643.10.1002/1097-0142(19931101)72:9<2638::AID-CNCR2820720919>3.0.CO;2-N
- D’Amico, A. V., Chen, M. H., Roehl, K. A., Catalona, W. J. (2004). Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. New Engl. J. Med., 351 (2), 125–135.10.1056/NEJMoa032975
- Eggener, S. E., Yossepowitch, O., Roehl, K. A. (2008). Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program. Urology, 71 (6), 1016–1019.10.1016/j.urology.2007.12.008
- Epstein, J. I., Allsbrook, W. C. J., Amin, M. B. (2005). ISUP grading committee. The 2005 International Society of Urologic Pathology (ISUP) Consensus Conference on Gleason grading of Prostatic Carcino-ma. Amer. J. Surg. Pathol., 29 (9), 1228–1242.
- Folkmanis, K., Eglitis, J., Jakubovskis, M., Lietuvietis, V., Folkmane, I, Isajevs, S. CD63 and DNA mismatch repair protein expression in prostate cancer. Proc. Latvian Acad. Sci., Section B, 75 (3), 180–185.10.2478/prolas-2021-0027
- Heidenreich, A. (2008). Identification of high-risk prostate cancer: Role of prostate-specific antigen, PSA doubling time, and PSA velocity. Eur. Urol., 54 (5), 976–977; discussion 978–979.10.1016/j.eururo.2008.06.077
- Ilic, D., O’Connor, D., Green, S. (2007). Screening for prostate cancer: A Cochrane systematic review. Cancer Causes Control., 18 (3), 279–285.10.1007/s10552-006-0087-6
- Khatami, A., Aus, G., Damber, J. E., Lilja, H., Lodding, P., Hugosson, J. (2007). PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section. Int. J. Cancer, 120 (1), 170–174.
- Loeb, S., Kettermann, A., Ferrucci, L., Landis, P., Metter, E. J., Carter, H. B. (2008). PSA doubling time versus PSA velocity to predict high-risk prostate cancer: Data from the Baltimore Longitudinal Study of Aging. Eur. Urol., 54 (5), 1073–1080.10.1016/j.eururo.2008.06.076
- Loeb, S., Metter, E. J., Kac, D. (2012). Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer. Brit. J. Urol. Int., 109 (4), 508–513.10.1111/j.1464-410X.2011.10900.x
- Loeb, S., Roehl, K. A., Helfand, B. T. (2010). Can prostate specific antigen velocity decrease insignificant prostate cancer detection? J. Urol., 183 (1), 112–116.10.1016/j.juro.2009.08.156
- Lorente, J. A., Morote, J., Raventos, C. (1996). Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J. Urol., 155 (4), 1348–1351.10.1097/00005392-199604000-00060
- Lu-Yao, G., Albertsen, P. C., Stamford, J. L. (2002). Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Con-necticut. Brit. Med. J., 325 (7367), 740.10.1136/bmj.325.7367.740
- McLaren, D. B., McKenzie, M., Duncan, G., Pickles, T. (1998). Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer, 82 (2), 342–348.
- Mottet, N., Cornford, P., van den Bergh, R. C. N., De Santis, M., Fanti, S., Gillessen, S., Grummet, J., Henry, A.M., Lam, T. B., Mason, M. D., van der Kwast, T. H. et al. (2020). Oncology Guidelines, Prostate Cancer. https://uroweb.org/guideline/prostate-cancer/ (accessed 14.07.2021).
- Moul, J. W., Wu, H., Sun, L. (2004). Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J. Urol., 171 (3), 1141–1147.10.1097/01.ju.0000113794.34810.d0
- O’Brien, M. F., Cronin, A. M., Fearn, P. A. (2009). Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pre-treatment PSA alone in patients treated with radical prostatectomy. J. Clin. Oncol., 27 (22), 3591–3597.10.1200/JCO.2008.19.9794
- Oudard, S., Banu, E., Scotte, F. (2007). Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann. Oncol., 18 (11), 1828–1833.10.1093/annonc/mdm332
- Post, P. N., Kil, P.J., Coebergh, J. W. (1999). Trends in survival of prostate cancer in southeastern Netherlands 1971-1989. Int. J. Cancer, 81 (4), 551–554.10.1002/(SICI)1097-0215(19990517)81:4<551::AID-IJC8>3.0.CO;2-5
- Pound, C. R., Partin, A. W., Eisenberger, M. A., Chan, D. W., Pearson, J. D., Walsh, P. C. (1999). Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 281 (17), 1591–1597.10.1001/jama.281.17.1591
- Pruthi, R. S., Johnstone, I., Tu, I. P., Stamey, T. A. (1997). Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer. Urology, 49 (5), 737–742.10.1016/S0090-4295(97)00231-8
- Raaijmakers, R., Wildhagen, M. F., Ito, K. (2004). Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Urology, 63 (2), 316–320.10.1016/j.urology.2003.09.028
- Ramirez, M. L., Nelson, E. C., Devere White, R. W. (2008). Current applications for prostate-specific antigen doubling time. Eur. Urol., 54 (2), 291–300.10.1016/j.eururo.2008.04.003
- Rana, A., Karamanis, K., Lucas, M. G. (1992). Identification of metastatic disease by T category, Gleason score and serum PSA level in patients with carcinoma of the prostate. Brit. J. Urol., 69 (3), 277–281.10.1111/j.1464-410X.1992.tb15528.x
- Ross, P. L., Mahmud, S., Stephenson, A. J., Souhami, L., Tanguay, S., Aprikian, A. G. (2004). Variations in PSA doubling time in patients with prostate cancer on “watchful waiting”: value of short-term PSADT determinations. Urology, 64 (2), 323–328.10.1016/j.urology.2004.03.020
- Schmid, H. P., McNeal, J. E., Stamey, T. A. (1993). Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer, 71 (6), 2031–2040.10.1159/000474708
- Schröder, F. H., Hugosson, J., Roobol, M. J. (2009). ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. New Engl. J. Med., 360 (13), 1320.
- Sengupta, S., Blute, M. L., Bagniewski, S. M. (2006). Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: Doubling time predicts survival. J. Urol., 175 (5),1684–1690.10.1016/S0022-5347(05)00978-X
- Spurgeon, S. E., Mongoue-Tchokote, S., Collins, L. (2007). Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy. Urology, 69 (5), 931–935.10.1016/j.urology.2007.01.075
- Stephenson, A. J., Aprikian, A. G., Souhami, L., Behlouli, H., Jacobson, A. I., Bégin, L. R., Tanguay, S. (2002). Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology, 59 (5), 652–656.10.1016/S0090-4295(02)01526-1
- Stewart, A. J., Scher, H. I., Chen, M. H. (2005). Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J. Clin. Oncol., 23 (27), 6556–6560.10.1200/JCO.2005.20.96616170163
- Thompson, I. M., Pauler, D. K., Goodman, P. J. (2004). Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. New Engl. J. Med., 350 (22), 2239–2246.10.1056/NEJMoa03191815163773
- Vickers, A. J., Savage, C., O’Brien, M. F. (2009). Systematic review of pre-treatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J. Clin. Oncol., 27 (3), 398–403.10.1200/JCO.2008.18.1685264585419064972
Language: English
Page range: 328 - 334
Submitted on: Jun 7, 2021
Accepted on: Jul 14, 2021
Published on: Nov 15, 2021
Published by: Latvian Academy of Sciences
In partnership with: Paradigm Publishing Services
Publication frequency: 6 times per year
Related subjects:
© 2021 Kristofs Folkmanis, Amrou Hajjar, Elizabete Junk, Evelīna Merdane, Valdis Folkmanis, Inese Folkmane, Sergejs Isajevs, published by Latvian Academy of Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.